Real-world 12-month outcomes of risdiplam in spinal muscular atrophy types 2 and 3
Background: Spinal muscular atrophy is a progressive genetic neuromuscular disorder characterized by degeneration of lower motor neurons and progressive muscle weakness. Risdiplam, an oral survival motor neuron 2 splicing modifier, has demonstrated efficacy in clinical trials; however, real-world data in older and chro...